These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 2467732

  • 21. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
    Yaginuma Y, Yamashita K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
    [Abstract] [Full Text] [Related]

  • 22. Immunohistochemical study of the ras oncogene expression in human breast lesions.
    Agnantis NJ, Petraki C, Markoulatos P, Spandidos DA.
    Anticancer Res; 1986 Sep; 6(5):1157-60. PubMed ID: 3541779
    [Abstract] [Full Text] [Related]

  • 23. Development of quantitative liquid competition radioimmunoassays for the ras oncogene and proto-oncogene p21 products.
    Caruso A, Schlom J, Vilasi V, Weeks MO, Hand PH.
    Int J Cancer; 1986 Oct 15; 38(4):587-95. PubMed ID: 3489681
    [Abstract] [Full Text] [Related]

  • 24. Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer.
    Nishio H, Nakamura S, Horai T, Ikegami H, Matsuda M.
    Cancer; 1992 Mar 01; 69(5):1130-6. PubMed ID: 1310887
    [Abstract] [Full Text] [Related]

  • 25. Association between the ras p21 oncoprotein in blood samples and breast cancer.
    Rundle A, Tang D, Brandt-Rauf P, Zhou J, Kelly A, Schnabel F, Perera FP.
    Cancer Lett; 2002 Nov 08; 185(1):71-8. PubMed ID: 12142081
    [Abstract] [Full Text] [Related]

  • 26. Preparation of anti-ras Mr 21,000 protein monoclonal antibodies and immunohistochemical analyses on expression of ras genes in human stomach and thyroid cancers.
    Yoshida K, Hamatani K, Koide H, Ikeda H, Nakamura N, Akiyama M, Tsuchiyama H, Nakayama E, Shiku H.
    Cancer Res; 1988 Oct 01; 48(19):5503-9. PubMed ID: 3046740
    [Abstract] [Full Text] [Related]

  • 27. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ.
    Ann Surg; 1995 Jun 01; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [Abstract] [Full Text] [Related]

  • 28. Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to C-MYC and C-Ha-ras cellular oncogenes.
    Pechoux C, Chardonnet Y, Chignol MC, Noël P.
    Histol Histopathol; 1994 Jan 01; 9(1):35-44. PubMed ID: 8003818
    [Abstract] [Full Text] [Related]

  • 29. The expression of ras oncogene in normal and pathological liver disease.
    Habib NA, Wood CB.
    Int Surg; 1986 Jan 01; 71(3):182-3. PubMed ID: 3771121
    [Abstract] [Full Text] [Related]

  • 30. [P21 expression of ras oncogene product in benign and malignant female mammary lesions].
    Zhang JZ, Fan SC, Liu HF.
    Zhonghua Bing Li Xue Za Zhi; 1994 Oct 01; 23(5):302-3. PubMed ID: 7874767
    [Abstract] [Full Text] [Related]

  • 31. Ras p21 expression in nephroblastoma group tumors.
    Aoki I, Yanoma S, Misugi K, Sasaki Y, Kikyo S.
    Acta Pathol Jpn; 1987 Dec 01; 37(12):1903-7. PubMed ID: 2833061
    [Abstract] [Full Text] [Related]

  • 32. Differential (Ha-, K- and N-) ras p21 expression in benign and malignant human thyroid tumors: an immunohistochemical study.
    Mizukami Y, Nonomura A, Michigishi T, Noguchi M, Nakamura S, Hashimoto T.
    Anticancer Res; 1995 Dec 01; 15(3):755-9. PubMed ID: 7645954
    [Abstract] [Full Text] [Related]

  • 33. Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents.
    DeBortoli ME, Abou-Issa H, Haley BE, Cho-Chung YS.
    Biochem Biophys Res Commun; 1985 Mar 15; 127(2):699-706. PubMed ID: 3884015
    [Abstract] [Full Text] [Related]

  • 34. ras oncogene is expressed in adenocarcinoma of the endometrium.
    Long CA, O'Brien TJ, Sanders MM, Bard DS, Quirk JG.
    Am J Obstet Gynecol; 1988 Dec 15; 159(6):1512-6. PubMed ID: 2462792
    [Abstract] [Full Text] [Related]

  • 35. ras oncogene p21 as a tumor marker in the cytodiagnosis of gastric and colonic carcinomas.
    Czerniak B, Herz F, Koss LG, Schlom J.
    Cancer; 1987 Nov 15; 60(10):2432-6. PubMed ID: 3311346
    [Abstract] [Full Text] [Related]

  • 36. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G, Antonaci A, Bosco D, Nardoni S, Melis M.
    J Exp Clin Cancer Res; 1999 Sep 15; 18(3):363-7. PubMed ID: 10606183
    [Abstract] [Full Text] [Related]

  • 37. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology.
    Saccani Jotti G, Fontanesi M, Bombardieri E, Gabrielli M, Veronesi P, Bianchi M, Becchi G, Bogni A, Tardini A.
    Int J Biol Markers; 1992 Sep 15; 7(1):35-42. PubMed ID: 1349907
    [Abstract] [Full Text] [Related]

  • 38. Immunohistochemical staining of colorectal tissues with monoclonal antibodies to ras oncogene p21 product and carbohydrate determinant antigen 19-9.
    Allen DC, Foster H, Orchin JC, Biggart JD.
    J Clin Pathol; 1987 Feb 15; 40(2):157-62. PubMed ID: 3546394
    [Abstract] [Full Text] [Related]

  • 39. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P.
    Am J Clin Pathol; 1992 Oct 15; 98(4):408-18. PubMed ID: 1357956
    [Abstract] [Full Text] [Related]

  • 40. Ha-ras oncogene product in human oral squamous cell carcinoma.
    Oku N, Shimada K, Itoh H.
    Kobe J Med Sci; 1989 Dec 15; 35(5-6):277-86. PubMed ID: 2699627
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.